Effect of Calcium Dobesilate on High Sensitivity CRP and Endothelin-1 Serum Levels in Patients with Diabetic Retinopathy

Abstract

Background and Objectives: Diabetic Retinopathy (DR) is a vascular complication of type 1 and type 2 diabetes mellitus. The aim of this study was to determine the effects of Calcium Dobesilate (CD) on decreasing Endothelin-1(ET-1) and high sensitivity C-Reactive Protein (hs-CRP) serum levels in patients with diabetic retinopathy. Materials and Methods: Ninety adults with type II diabetes having DR complication were included in this double-blind randomized clinical trial study. Patients categorized in two groups of case (diabetic retinopathy patents treated with CD) and control (diabetic retinopathy patents without CD treatment), age and sex-matched randomly between two groups during seventeen month period in Tabriz Nikookari eye Hospital and Sheikholrais clinical center. The case group received 500mg of CD for three month, The serum level of hs-CRP and ET-1, was recorded in all patients before and after administration of CD and compared between both groups. Results: Ninety patients with diabetic retinopathy, including of 30 males and 60 females, with the mean age of 59.18±7.13 years were enrolled in the study. The mean level of serum endothelin-1 was significantly different in the case group than control group after treatment with CD as well (0.69±0.32 pg/ml vs. 0.86±0.30 pg/ml; p=0.005), and also there was a significant different of mean serum level of hs-CRP after treatment with Doxium between the case and control group, as well (3.28± 3.28 mg/L vs. 4.67±3.75 mg/L; p=0.006; respectively). Conclusions: Treatment with CD can decrease the serum levels of ET-1 and hs-CRP as two important inflammatory biomarkers in patients with diabetic retinopathy. More studies are recommended to be carried out in this regard.

Keywords: Diabetic Retinopathy, Calcium Dobesilate (Doxium), Endothelin-1, High sensitivity CRP